CN113185608A - High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof - Google Patents

High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof Download PDF

Info

Publication number
CN113185608A
CN113185608A CN202110498615.1A CN202110498615A CN113185608A CN 113185608 A CN113185608 A CN 113185608A CN 202110498615 A CN202110498615 A CN 202110498615A CN 113185608 A CN113185608 A CN 113185608A
Authority
CN
China
Prior art keywords
chain variable
variable region
seq
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110498615.1A
Other languages
Chinese (zh)
Other versions
CN113185608B (en
Inventor
胡萍
辛洪波
王纯艳
刘苏俊
张文华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanchang University
Original Assignee
Nanchang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanchang University filed Critical Nanchang University
Priority to CN202110498615.1A priority Critical patent/CN113185608B/en
Priority to CN202210649220.1A priority patent/CN115260307B/en
Priority to CN202210649233.9A priority patent/CN115260308B/en
Priority to CN202210655968.2A priority patent/CN114957458B/en
Priority to CN202210655944.7A priority patent/CN114920835B/en
Publication of CN113185608A publication Critical patent/CN113185608A/en
Application granted granted Critical
Publication of CN113185608B publication Critical patent/CN113185608B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Abstract

The invention relates to a fully human monoclonal antibody of high affinity anti-rabies virus, belonging to the field of biological immunology. The heavy chain variable region of the monoclonal antibody or the binding fragment thereof has a nucleotide sequence of the heavy chain variable region as shown in any one of SEQ ID Nos. 11, 13, 15, 17 and 19; and the variable region of the light chain as set forth in any one of SEQ ID Nos. 12, 14, 16, 18 and 20. The invention also provides a coding gene, an expression vector, application and a composition of the antibody. Rabies Glycoprotein (GP) is the only protective antigenic protein on the surface of the virus. The invention successfully constructs a prokaryotic expression vector of rabies virus specific antigen protein, and expresses and purifies the prokaryotic expression vector by utilizing an escherichia coli prokaryotic system, and the antigen protein is successfully used for screening antibodies. And 5 specific fully human monoclonal antibody sequences aiming at rabies virus GP fragments are successfully screened by using the screening platform, so that a foundation is laid for clinically developing an antibody medicament for treating rabies.

Description

High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof
Technical Field
The invention relates to the field of biological immunology, in particular to a fully human monoclonal antibody of high-affinity anti-rabies virus and application thereof.
Background
Rabies is an acute infectious disease that seriously affects the central nervous system and is mainly caused by Rabies virus (RABV), and is a type b infectious disease in the classification of infectious diseases in China. The first records about rabies in the world begin in Meisuodamian before 4300 years, and the first written records about rabies in China appear in the left-handed courseware of 2500 years so far. Many studies suggest that rabies originates in asia or europe, introduced into the western hemisphere in 18 th century or europe, and 19 th time found in south america. Rabies is currently present in every continent, except antarctica, covering over 100 countries. The virus infects the body mainly through damaged skin, mucous membrane or respiratory tract, and saliva is one of the main infection routes. Almost all warm mammalian animals, such as raccoons, skunks, bats, foxes, are RABV hosts, and the primary infectious source is the diseased or virus-bearing canine species[7]. Most of human rabies is mainly caused by bite of sick animals, and some patients are caused by scratching or contamination of wounds, mucous membranes and the like, and there are few cases of attack caused by transplantation of organs or tissues donated by the patients. RABV acts primarily in the central nervous system and is present in large amounts in the cerebrospinal fluid of susceptible animals. Human rabies is mainly manifested as acute progressive encephalomyelitis, and usually occurs in two forms: manic rabies accompanied by indirect excitement and hallucination accompanied by symptoms such as wind fear, water fear, and vocal fear usually dies within 7 days, and paralytic rabies characterized by muscle weakness usually dies within 14 days. The latent period of the disease is generally 3 weeks to 3 months, within 10 days or as long as 1 yearAnd the above reports are very rare[9]。
According to the World Health Organization (WHO) statistics, 6 million people die of rabies annually worldwide, most of them occur in the sub-african region, and 1 person dies per 10min on average, 50% of them occur in children under 15 years old. In addition, about 2 million dogs are killed by innocent insect killers each year, with up to 38 dogs killed by rabies per minute. Chinese rabies mortality is second in Asia, and is second only in India, and the number of deaths is higher than the first three of the number of deaths of infectious diseases in China. China has more than 100 billion yuan of capital for rabies epidemic prevention every year, but the actual effect is not good. Over 1500 million people worldwide receive vaccination after rabies exposure every year, causing economic losses of up to $ 40 million.
Since the first antibody drug Orthoclone was marketed in 1992, 63 antibody drugs were marketed in 2016, and an average of 2.5 antibody drugs were marketed every year, with increasing rates. Antibody drugs have long been reported for the treatment of viral infectious diseases, and the case of antisera for the treatment of SARS and severe hepatitis H5N1 HCV infected persons has demonstrated the important role played by antibodies in the treatment of viral infections. The market vacancy of the rabies monoclonal antibody at home and abroad is large currently, a recombinant humanized rabies antibody NM57s/NC08 injection researched and developed by North China pharmaceutical in China enters a stage III clinical test stage in 2018, a stage III clinical test report is obtained in 4 months in 2020, and the monoclonal antibody is a combined preparation obtained by combining two monoclonal antibodies NM57S and NC08 and needs to be combined with a vaccine for use. In foreign markets, mabs RabiMabs developed by Zydus cadila were qualified by the U.S. Food and Drug Administration (FDA) for rabies prevention in 2019, month 5, and were approved by the indian Drug Administration (DCGI) on day 3, month 9 of the same year for rabies post-exposure prophylaxis in combination with a vaccine. The recombinant anti-RABV mab injection, RABIShield, co-developed by the Indian serum institute and Mass Biologics, was approved for marketing in India in 2016, 12 months. The whole humanized monoclonal antibody for preventing and treating rabies is not available in the global market, once the product is marketed and produced in a large scale, the cost for preventing and treating rabies is greatly reduced, and the product has competitive advantages incomparable with the traditional blood products and vaccines. Therefore, we hope to screen one or more broad-spectrum anti-rabies fully humanized monoclonal antibodies with therapeutic action by a specific screening method after in vitro activation of the special human memory B cells in the laboratory, and improve the current situation of rabies prevention and treatment difficulty.
Disclosure of Invention
The inventor obtains a fully human monoclonal antibody with broad-spectrum combination with rabies virus through deep research, the monoclonal antibody is fully human, and the variable regions and the constant regions of the heavy chain and the light chain of the monoclonal antibody are all derived from human genes, so the monoclonal antibody has the characteristics of low immunogenicity and high safety.
The 1861 rabies virus gene was first reported to be a single-stranded non-segmented negative-strand RNA virus with a bullet-like shape, a diameter of about 75nm, a length of 100-300 nm, and a length of about 12 kb. Viral RNA encodes 5 proteins, in turn, the nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein (G), and the polymerase large protein (L). The invention selects G protein as antigen epitope, the G protein is composed of 1575 nucleotides, is the only protein located on the surface of virus, can combine with intracellular receptor acetylcholine receptor to make the virus have neurotropic property, can induce host to generate neutralizing antibody, and has protective effect.
One aspect of the present invention provides a fully human monoclonal antibody against rabies virus having a heavy chain variable region and a light chain variable region:
(I) the amino acid sequence of the heavy chain variable region has the nucleotide sequence of the heavy chain variable region shown in any one of SEQ ID NOs 11, 13, 15, 17 and 19; or has an amino acid sequence which is formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in any one of SEQ ID NO. 11, 13, 15, 17 and 19 and has the same function;
(II) the amino acid sequence of the light chain variable region has the nucleotide sequence of the light chain variable region as shown in any one of SEQ ID NOs 12, 14, 16, 18 and 20; or an amino acid sequence which is formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in any one of SEQ ID NO 12, 14, 16, 18 and 20 and has the same function.
Preferably, the monoclonal antibody has any one of the following groups of heavy chain variable regions and light chain variable regions:
(i) the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:11 (1H)10) (ii) a The amino acid sequence of the light chain variable region is shown as SEQ ID NO:12 (3 lambda)5)；
(ii) The amino acid sequence of the heavy chain variable region is shown as SEQ ID NO:13 (1H)16) (ii) a The amino acid sequence of the light chain variable region is shown as SEQ ID NO:14 (3 lambda)7)；
(iii) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:15 (1H)17) (ii) a The amino acid sequence of the light chain variable region is shown as SEQ ID NO:16 (3 lambda)8)；
(iv) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:17 (1H)3) (ii) a The amino acid sequence of the light chain variable region is shown as SEQ ID NO:18 (3 lambda)1)；
(v) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:19 (1H)18) (ii) a The amino acid sequence of the light chain variable region is shown as SEQ ID NO:20 (3 lambda)10)。
The monoclonal antibody provided by the invention can be specifically combined with rabies virus G protein.
In another aspect of the present invention, the present invention also provides a nucleic acid molecule encoding the above monoclonal antibody.
Preferably, the nucleic acid molecule has the nucleotide sequence of the heavy chain variable region as set forth in any one of SEQ ID NOs 1, 3, 5, 7 and 9; and the variable region of the light chain as set forth in any one of SEQ ID NOs 2, 4, 6, 8 and 10.
More preferably, the nucleic acid molecule has any one of the following sets of heavy chain variable region and light chain variable region:
(i) the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO:1 (1H)10) (ii) a The variable region of the light chain has the nucleotide sequence shown in SEQ ID NO:2 (3 lambda)5)；
(ii) The nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO:3 (1H)16) (ii) a The variable region of the light chain has the nucleotide sequence shown in SEQ ID NO:4 (3 lambda)7)；
(iii) The variable region of the heavy chain has the nucleotide sequence shown in SEQ ID NO:5 (1H)17) (ii) a The variable region of the light chain has the nucleotide sequence shown in SEQ ID NO:6 (3 lambda)8)；
(iv) The variable region of the heavy chain has the nucleotide sequence shown in SEQ ID NO:7 (1H)3) (ii) a The variable region of the light chain has the nucleotide sequence shown in SEQ ID NO:8 (3 lambda)1)；
(v) The nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO:9 (1H)18) (ii) a The variable region in the light chain has the nucleotide sequence shown in SEQ ID NO:10 (3 lambda)10)。
In another aspect of the invention, there is provided an expression vector comprising the nucleic acid molecule described above.
The expression vector may contain, in addition to the nucleic acid molecule described above, a suitable promoter or control sequence. The vector may be used to transform an appropriate host cell so that it can express the protein.
In another aspect of the present invention, there is provided a host cell comprising the above-described expression vector.
The host cell may be a prokaryotic cell, such as a bacterial cell; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples are: bacterial cells such as E.coli, Streptomyces; salmonella typhimurium; fungal cells such as yeast; a plant cell; insect cells such as Drosophila S2 or Sf 9; animal cells such as CHO, COS7, NSO or Bowes melanoma cells, etc. Particularly suitable host cells for use in the present invention are eukaryotic host cells, especially mammalian cells, such as 293 cells.
In another aspect of the present invention, there is provided a method for preparing the monoclonal antibody, comprising the steps of:
(1) memory B cell sorting: separating peripheral blood mononuclear cells from blood samples of volunteers infected with rabies viruses, and sorting the peripheral blood mononuclear cells to obtain memory B cells;
(2) in-vitro activation culture and positive hole screening of memory B cells: activating the memory B cells into plasma cells, detecting secretory IgG antibodies of the memory B cells after the memory B cells are activated into the plasma cells in vitro by ELISA, and screening to obtain positive holes;
(3) constructing and screening an antibody variable region gene library: carrying out reverse transcription on the positive hole cells to obtain cDNA, and amplifying genes of heavy chain variable regions and light chain variable regions of the antibodies;
(4) constructing a library of antibody gene heavy chain variable regions and light chain variable regions: respectively connecting the amplified genes of the heavy chain variable region and the light chain variable region of the antibody to an expression vector;
(5) screening of antibody heavy chain variable region and light chain variable region genes: the recombinant plasmid was co-transfected into HEK293T cells for expression.
In another aspect of the invention, the monoclonal antibody or the fragment thereof is provided for use in the preparation of a medicament for detecting, treating and preventing rabies virus infection.
In another aspect of the present invention, there is provided a composition comprising an antibody mixture of one or more of said monoclonal antibodies in a therapeutically effective amount, and a pharmaceutically acceptable carrier.
The term "pharmaceutically acceptable" as used herein means that the molecular entities and compositions do not produce adverse, allergic, or other untoward reactions when properly administered to an animal or human. As used herein, a "pharmaceutically acceptable carrier" should be compatible with, i.e., capable of being blended with, the monoclonal antibody of the invention or fragment thereof without substantially reducing the effectiveness of the composition as is often the case.
Specific examples of some substances that may serve as pharmaceutically acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; powdered gum tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyhydric alcohols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; a colorant; a flavoring agent; tabletting agents, stabilizers; an antioxidant; a preservative; pyrogen-free water; isotonic saline solution; and phosphate buffer, and the like.
The compositions of the present invention may be formulated into various dosage forms as desired, and may be administered by a physician in a dosage amount beneficial to the patient, depending on such factors as the type, age, weight and general condition of the patient, the mode of administration, and the like. Administration may be by injection or other therapeutic means, for example.
The pharmaceutical composition may comprise two or more monoclonal antibodies or fragments thereof having binding activity to rabies virus.
In another aspect of the present invention, there is provided a kit for detecting rabies virus, comprising said monoclonal antibody or fragment thereof.
Based on the monoclonal antibody or the fragment thereof, the kit for conveniently, quickly and accurately detecting the rabies virus can be prepared. As a detection method of the present invention, an indirect ELISA method is used, in which an antigen to be detected is coated on a solid phase carrier, and detection is performed using the monoclonal antibody or the fragment thereof of the present invention. In a preferred embodiment of the present invention, the monoclonal antibody or a fragment thereof is an antibody, and is detected according to the principle of double antibody sandwich method. The double antibody sandwich method is conventionally performed by immobilizing a primary antibody (e.g., the monoclonal antibody of the present invention) on a carrier, reacting the primary antibody with an antigen, washing, reacting with a secondary antibody (the secondary antibody carries a detectable signal or can bind to a substance carrying a detectable signal), and detecting a signal by a chemiluminescent or enzyme-linked chromogenic reaction. The double antibody sandwich method is particularly suitable for the detection of antigens having two or more epitopes.
For convenience in detection, the kit may further comprise, in addition to the monoclonal antibody or fragment thereof of the present invention, other detection reagents or auxiliary reagents, such as those conventionally used in ELISA kits, the properties of which and their formulation methods are well known to those skilled in the art, such as color developing agents, labels, secondary antibodies, anti-antibodies, sensitizers, and the like. It will be understood by those skilled in the art that various modifications of the detection kit are encompassed by the present invention as long as the monoclonal antibody or fragment thereof of the present invention is utilized therein as a reagent for recognizing rabies virus.
In addition, instructions for use may be included in the kit to instruct the method of use of the reagents loaded therein.
After obtaining the monoclonal antibody or the fragment thereof provided by the present invention, various immunologically related methods can be used to detect rabies virus Glycoprotein (GP) in the sample, so as to know whether the donor of the sample to be detected is infected with rabies virus, and these methods are all included in the present invention. Preferably, the method is for the purpose of non-disease diagnosis.
In another aspect of the invention, there is provided a method of non-therapeutically inhibiting rabies virus, said method comprising administering to a patient an effective amount of said monoclonal antibody or fragment thereof.
In another aspect of the present invention, there is provided a method for non-therapeutic detection of rabies virus, wherein the monoclonal antibody or fragment thereof is contacted with a test sample, and the presence and amount of rabies virus is detected by detecting the binding of the monoclonal antibody or fragment thereof to the test sample.
As used herein, the term "test sample" encompasses a variety of sample types, including blood and other bodily fluid samples of biological origin, solid tissue samples such as biopsy tissue samples or tissue cultures, or cells derived therefrom or progeny thereof. The term also includes samples that have been treated by any means after they have been obtained, for example by treating with reagents, solubilizing, or enriching certain components such as proteins or polynucleotides. The term encompasses various clinical samples obtained from any species, also including cultured cells, cell supernatants and cell lysates.
Has the advantages that: compared with the prior art, the fully human monoclonal antibody for resisting the rabies viruses is successfully screened and prepared, has the characteristic of high affinity, can be specifically combined with the rabies viruses, and can obviously resist the rabies viruses. Compared with a mouse antibody, the gene of the fully human antibody is completely derived from the human gene, has no other species of components, does not generate toxic and side effects such as an anti-mouse antibody and the like in a human body, has better biocompatibility, is more suitable and has more potential to become a macromolecular drug for treating rabies viruses, and provides great guarantee for the standardized production of finished drugs of the antibody.
Drawings
Figure 1 positive well cell screen. A: elisa screening memory B cell positive holes, wherein red is positive hole cells for plasmid construction; b: and (5) carrying out agarose electrophoresis detection on the sample, wherein M is a DNA molecular standard.
FIG. 2 shows the results of electrophoresis of gene libraries for heavy chain VH and VH' and light chain VK and Vlambda variable regions of sample antibodies; m is a DNA molecular standard.
FIG. 3 construction of gene library of heavy and light chain variable region of antibody. A: carrying out enzyme digestion electrophoresis on the target plasmid and the carrier plasmid of the sample; b: K. performing secondary enzyme digestion electrophoresis on the IgK; c: the result of transformation of recombinant plasmid TOP 10; d: and (3) carrying out enzyme digestion electrophoresis identification on the recombinant plasmid, wherein M is a DNA molecular standard.
FIG. 4 shows the results of screening the combination of heavy and light chain variable region genes of antibodies.
Detailed Description
The following examples further illustrate the present invention but are not to be construed as limiting the invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention.
Experimental procedures without specific conditions noted in the examples, generally following conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the laboratory Manual (New York: Cold Spring harbor laboratory Press,1989), or according to the manufacturer's recommendations.
Example 1: preparation of fully human monoclonal antibody of (1)
1. Sorting of memory B cells
1.1 acquisition of peripheral blood mononuclear cells
Fresh 3.5ml of blood was drawn from the rabies virus infected volunteers and placed in an anticoagulation tube. Diluting fresh anticoagulated whole blood and PBS in equal volume, slowly adding into lymphocyte separation liquid (Solarbio, Cat. NO. P8610) to be centrifuged, carefully taking out, sucking the second cloudy mononuclear cell layer, washing in a centrifuge tube filled with PBS, centrifuging to remove supernatant, washing with PBS for 1 time, and collecting the cells which are Peripheral Blood Mononuclear Cells (PBMC).
1.2 memory B cell sorting
The supernatant was removed by centrifugation of PBMC of the isolated volunteers every 10 th7The individual cells were resuspended in cell pellet with 40. mu.L buffer. Add 10. mu.L of Biotin-Antibody Cocktail, mix well and incubate for 5min in a refrigerator at 4 ℃. Adding 30 μ L buffer solution and 20 μ L Anti-Biotin MicroBeads, mixing well, and standing in refrigerator at 4 deg.C for 10 min. Adding 1-2mL buffer solution to wash the cells, centrifuging at 1000rpm for 10min, and removing the supernatant. Resuspend the cells with 500. mu.L buffer. The column was placed on a magnet and the column was washed with 3mL of buffer. The cell suspension is applied to a sorting column to prevent the formation of air bubbles, and the outflowing unlabeled cells are collected. The column was washed 3 times with 500 μ L of buffer and all the eluates were collected, i.e. the suspension containing B cells. The above experiment used the "human memory B cell sorting magnetic bead" kit (Miltenyi, Cat. NO. 99-130-.
The cells were counted, centrifuged at 1000rpm for 10min, the supernatant was thoroughly removed, and the cell pellet was resuspended in 80. mu.L of buffer. Add 20. mu.L of CD27 MicroBeads to the cells, mix well, incubate for 15min in a refrigerator at 4 ℃. Cells were washed with 1-2mL of buffer and centrifuged at 1000rpm for 10min to remove the supernatant completely. Resuspending with 500. mu.L buffer solution to less than or equal to 108A cell. The post was placed on the magnet. The column was washed with the appropriate volume of buffer. The cell suspension was applied to the column. The eluted unlabeled cells were collected and the column was washed 3 times with the appropriate volume of buffer. Collecting all the eluent, namely the suspension containing the unlabeled cells, and adding the washing liquid after the liquid in the column is drained in the washing process. Removing the column from the separator and placing it on a collection tubeThe buffer was pipetted onto the column and the piston was immediately forced to wash out the magnetic bead labeled cells. The cell is a memory B cell. Counting the sorted memory B cells. The above experiment used the "human B cell CD27 sorting beads" kit (Miltenyi, Cat. NO. 99-130-.
2. In-vitro activation culture and positive hole screening of memory B cells
The method comprises the steps of collecting 50ml of fresh whole blood of 2 volunteers with high RABV IgG antibody expression in serum, separating memory B cells by a magnetic bead sorting method, culturing the memory B cells and feeder layer cells in a U-shaped 96-well plate together, detecting the expression of the antibody in the supernatant by Elisa after culturing for 10 days, wherein the result is shown in table 1 (figure 1A is a quantization diagram), screening 3 positive cell wells with the highest OD values, sequentially numbering I, II and III (respectively containing 10, 50 and 100 memory B cells), extracting RNA, carrying out reverse transcription to cDNA, and then verifying by taking GAPDH as a primer, wherein the result is shown in figure 1B, the single normal 3T3 cells have no band, and the bands of the samples of the positive wells I, II and III are all obvious at 250bp, which indicates that the RNA of the screened positive well cells secreting the antibody is successfully extracted, and the later-stage plasmid construction can be carried out.
TABLE 1 Elisa screening of Positive well cells secreting anti-rabies Virus antibodies
Figure BDA0003055519830000081
Figure BDA0003055519830000091
TABLE 1 detection of B cell supernatant specificity using Enzyme-linked immunosorbent assay (ELISA).
3. Construction and screening of antibody variable region gene library
RNA of each cell is extracted from samples I, II and III, variable regions of heavy chain VH, light chain VK and V lambda of the antibody are amplified by a nested PCR two-round amplification method, and the variable regions of the heavy chain are divided into two parts of VH and VH' for respective amplification due to the large molecular weight and the longer amino acid sequence. And detecting the amplification result by agarose gel electrophoresis, and recovering the gel to obtain the DNA of the amplified antibody heavy chain VH and VH' and light chain VK and V lambda variable region fragments. The electrophoresis results are shown in FIG. 2, and the antibody heavy chain VH and VH' and light chain VK and V lambda variable regions have obvious bands at 400bp, which is expected.
3.1 construction of antibody heavy and light chain variable region Gene library
Carrying out enzyme digestion on the amplified heavy chain VH and VH' variable region genes, light chain VK and V lambda variable region genes and constant region vector plasmids IgH, IgK and Ig lambda according to the specification of an enzyme digestion kit, wherein the electrophoresis result is shown in figures 3A and 3B, the target gene has an obvious strip at 400bp, the vector plasmid has an obvious strip at 5000bp, and the result accords with the expectation. Subsequently, the objective plasmid and the vector plasmid were subjected to enzyme ligation reaction, and the recombinant plasmid was transformed by TOP10 cells, as a result, FIG. 3C shows that the control plate was grown aseptically and each experimental group was full of colonies. After the plasmid is extracted slightly, the recombinant plasmid is subjected to enzyme digestion for identification, the result is shown in figure 3D, and the samples of the recombinant plasmids I, II and III screened earlier are subjected to enzyme digestion to obtain two bands with different molecular weights, wherein the heavy chain VH and VH' of the target plasmid and the light chain VK and Vlambda of the target plasmid have obvious bands at 400bp bands, the carrier plasmids IgH, IgK and Ig lambda have obvious bands at 5000bp bands, and the result is expected to indicate that the construction of the recombinant plasmid of the antibody heavy-light chain variable region gene library is successful.
3.2 screening of monoclonal antibodies
We screened monoclonal antibody sequences from a library of heavy and light chain individual total plasmids. The method comprises the following steps: sequentially transfecting HEK239T cells with 3 screened sample heavy-light chain combinations including IH + IK, IH + Ilambda, IIH + IIK, IIH + IIlambda, IIIH + IIIK and IIIH + IIIlambda, and screening a plasmid combination secreting a specific antibody: screening IIIH and IIIlambda according to OD values, averagely dividing transformed IIIH and IIIlambda into 8 parts, sequentially numbering extracted plasmids as 1H, 2H and 3H.. multidot.8H and 1 lambda, 2 lambda and 3 lambda.. multidot.8 lambda, respectively combining IIIH with 1 lambda, 2 lambda and 3 lambda.. multidot.8 lambda., and IIIlambda total with 1H, 2H and 3H.. multidot.8H, and sequentially transfecting HEK239 cells to screen plasmid combinations secreting specific antibodies. ③: we screened 1H and 3. lamda in small parts of IIIH and IIIlamda 8, and transferred 20ng of plasmidChanging, respectively selecting 30 monoclonal colonies, sequentially numbering as 1H1、1H2、1H3.......1H30And 3 λ1、3λ2、3λ3.......3λ301H and 3 λ are also used1、3λ2、3λ3.......3λ303 λ and 1H1、1H2、1H3.......1H30HEK239T cells were transfected in combination to select plasmid combinations secreting specific antibodies. Fourthly, the method comprises the following steps: we selected 10 heavy chain monoclonal plasmids with higher OD values from them: 1H3、1H10、1H17、1H18、1H21、1H23、1H24、1H27、1H28、1H9And 10 light chain monoclonal plasmids: 3 lambda2、3λ6、3λ7、3λ8、3λ10、3λ11、3λ14、3λ15、3λ20、3λ29. Combining the heavy-light chain monoclonal plasmids two by two, sequentially transfecting HEK293T cells with the 100 plasmid combinations, screening out the monoclonal plasmid combination secreting specific antibodies, and detecting the antibody expression condition in cell supernatant by Elisa. Table 2 (FIG. 4 is a quantitative chart) shows Elisa results of the first 20 plasmid combinations with higher OD among 100 combinations.
TABLE 2 Elisa screening of monoclonal antibody heavy and light chain combinatorial plasmids
Figure BDA0003055519830000101
Screening to obtain heavy and light chain monoclonal sequences, selecting 5 heavy and light chain monoclonal sequences respectively, and performing in-vitro transfection expression in a one-to-one matching way, wherein the heavy chain monoclonal sequences of the 5 heavy chains: 1H10,1H16,1H17,1H3,1H218And 5 light chain monoclonal sequences: 3 lambda5，3λ7,3λ8,3λ1,3λ10And finally obtaining 5 monoclonal antibodies with high affinity after ELISA screening, wherein the antibody combination is as follows: 1H10+3λ5、1H16+3λ7、1H17+3λ8、1H3+3λ1、1H18+3λ10(the results correspond to FIG. 4). The five plasmid combinations had OD values above 1.1, with very good affinity.
The foregoing descriptions of specific exemplary embodiments of the present invention have been presented for purposes of illustration and description. It is not intended to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teaching. The exemplary embodiments were chosen and described in order to explain certain principles of the invention and its practical application to enable one skilled in the art to make and use various exemplary embodiments of the invention and various alternatives and modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims and their equivalents.
SEQUENCE LISTING
<110> university of Nanchang
<120> high-affinity fully human monoclonal antibody against rabies virus and application thereof
<130> 1
<160> 20
<170> PatentIn version 3.5
<210> 1
<211> 356
<212> DNA
<213> 1H10 heavy chain variable region nucleotide sequence
<400> 1
gtacattccg aggtgcagct ggtgcagtct gggggaggct tggtccagcc tggggggtcc 60
ctgagactct cctgtgcagc ctctgtggag gcctttagta catattggat gaactgggtc 120
cgccaggctc cagggaaggg gctggagtgg gtggccaaca taaaccgaga tggaagtcag 180
aaatactatg tggactctgt ggagggccga ttcaccatct ccagagacaa cgccaagagc 240
tcactgtatc tgcaaatgaa cagcctgaga gccgatgaca cggctgtcta ttactgtatg 300
agtggctacg attccggcca ctggggccag ggatccctgg tcaccgtctc ctcagc 356
<210> 2
<211> 392
<212> DNA
<213> 3 lambda 5 light chain variable region nucleotide sequence
<400> 2
ttcaattccc aggctgtggt gactcaggag ccctcactga ctgtgtcccc aggagggaca 60
gtcactctca cctgtggctc cagtactgga gctgtcacca gtggtcttta tgcctactgg 120
ttccagcaga agcctggcca agtcccccgg acactgagta ctggagctgt catttataat 180
ataagcaaca aacagtcctg gacccctgcc cggttctcag gctccctcct tgggggcaaa 240
gctgccctga ccctttcggg tgcgcagcct gaggatgagg ctgactatta ctgcttgctc 300
tcctatagtc gtactcgggt gttcggcgga gggaccaagc tgaccgtcct aggtcagccc 360
aaggctgccc cctcggtcac tctgttccca cc 392
<210> 3
<211> 356
<212> DNA
<213> 1H16 heavy chain variable region nucleotide sequence
<400> 3
gtacattctg aagtgcagct ggtggagtct gggggaggct tggtccagcc tggggggtcc 60
ctgagactct cctgtgcagc ctctggattc acctttagta catattggat gaactgggtc 120
cgccaggctc cagggaaggg gctggagtgg gtggccaaca taaaccgaga tggaagtcag 180
aaatactatg tggactctgt ggagggccga ttcaccatct ccagagacaa cgccaagagc 240
tcactgtatc tgcaaatgaa cagcctgaga gccgatgaca cggctgtcta ttactgtatg 300
agtggctacg attccggcca ctggggccag ggatccctgg tcaccgtctc ctcagc 356
<210> 4
<211> 386
<212> DNA
<213> 3 lambda 7 light chain variable region nucleotide sequence
<400> 4
tccaattctc aggctgtggt gacccaggag ccctcactga ctgtgtcccc aggagggaca 60
gtcactctca cctgtggctc cagtactgga gctgtcacca gtggtcttta tgcctactgg 120
acagtcactt tccagcagaa gcctggccaa gtcccccgga cactgattta taatataagc 180
aacaaacagt cctggacccc tgcccggttc tcaggctccc tccttggggg caaagctgcc 240
ctgacccttt cgggtgcgca gcctgaggat gaggctgact attactgctt gctctcctat 300
agtcgtactc gggtgttcgg cggagggacc aagctgaccg tcctaggtca gcccaaggct 360
gccccctcgg tcactctgtt cccgcc 386
<210> 5
<211> 350
<212> DNA
<213> 1H17 heavy chain variable region nucleotide sequence
<400> 5
gtacattctg aggtgcagct gttggagtct gggggaggct tggtccagcc tggggggtcc 60
ctgagactct cctgtgcagc ctctggattc acctttagta catattggat gaactgggtc 120
cgccaggctc cagggaaggg gctggagtgg gtggccaacc gagatggaag tcagaaatac 180
tatgtggact ctgtggaggg ccgattcacc atctccagag acaacgccaa gagctcactg 240
tatctgcaaa tgaacagcct gagagccgat gacacggctg tctattactg tatgagtggc 300
tacgattccg gccactgggg ccagggatcc acggtcaccg tctcctcagc 350
<210> 6
<211> 371
<212> DNA
<213> 3 lambda 8 light chain variable region nucleotide sequence
<400> 6
tcttgggcca attttatgct gactcaggag ccctcactga ctgtgtcccc aggagggaca 60
gtcactctca cctgtggctc cagtactgga gctgtcacca gtggtcttta tgcctactgg 120
ttccagcaga agcctggcca agtcccccgg acactgattt ataatataag caacaaacag 180
tcctggaccc ctgcccggtt ctcaggctcc ctccttgggg gcaaagctgc cctgaccctt 240
tcgggtcctg aggatgaggc tgactattac tgcttgctct cctatagtcg tactcgggtg 300
ttcggcggag ggaccaagct gaccgtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccgc c 371
<210> 7
<211> 383
<212> DNA
<213> 1H3 heavy chain variable region nucleotide sequence
<400> 7
gtacattctc aggtgcagct ggtggagtct gggggaggcg tggtccagcc tgggaggtcc 60
ctgagactct cctgtgcagc ctctggattc accttcagta gctatgctat gcactgggtc 120
cgccaggctc caggcaaggg gctggagtgg gtggcagtta tatcatatga tggaaataaa 180
tactacgcag actccgtgaa gggccgattc accatctcca gagacaattc caagaacacg 240
ctgtatctgc aaatgaacag cctgagagat gaggacacgg ctgtgtatta ctgtgcgaga 300
gctcctgatt gtagtggtgg tagctgctcc actgaatact tccagcactg gggccagggc 360
accctggtca ccgtctcctc agc 383
<210> 8
<211> 371
<212> DNA
<213> 3 lambda 1 light chain variable region nucleotide sequence
<400> 8
tcctgggccc agtctgtgct gacgcaggag ccctcactga ctgtgtcccc aggagggaca 60
gtcactctca cctgtggctc cagtactgga gctgtcacca gtggtcttta tgcctactgg 120
ttccagcaga agcctggcca agtcccccgg acactgattt ataatataag caacaaacag 180
tcctggaccc ctgcccggtt ctcaggctcc ctccttgggg gcaaagctgc cctgaccctt 240
tcgggtgcgc agcctgagga tgaggctgac tattactgct tgctctccta tagtcgtact 300
cgggtgttcg ggaccaagct gaccgtccta ggtcagccca aggctgcccc ctcggtcact 360
ctgttcccac c 371
<210> 9
<211> 368
<212> DNA
<213> 1H18 heavy chain variable region nucleotide sequence
<400> 9
gtacattccg aggtgcagct ggtgcagtct gggggaggct tggtccagcc tggggggtcc 60
ctgagactct cctgtgcagc ctctggattc acctttagta catattggat gaactgggtc 120
cgcctctccc agactccagg gaaggggctg gagtgggtgg ccaacataaa ccgagatgga 180
agtcagaaat actatgtgga ctctgtggag ggccgattca ccatctccag actctccgac 240
aacgccaaga gctcactgta tctgcaaatg aacagcctga gagccgatga cacggctgtc 300
tattactgta tgagtggcta cgattccggc cactggggcc agggatccac ggtcaccgtc 360
tcctcagc 368
<210> 10
<211> 368
<212> DNA
<213> 3 lambda 10 light chain variable region nucleotide sequence
<400> 10
tccaattccc agactgtggt gacccaggag ccctcactga ctgtgtcccc aggagggaca 60
gtcactctca cctgtggctc cagtactgga gctgtcacca gtggtcttta tgcccagcag 120
aagcctggcc aagtcccccg gacactgatt tataatataa gcaacaaaca gtcctggacc 180
cctgcccggt tctcaggctc cctccttggg ggcaaagctg ccctgaccct ttcgggtgcg 240
cagcctgagg atgaggctga ctattactgc ttgctctcct atagtcgtac tcgggtgttc 300
ggcggaggga ccaagctgac cgtcctaggt cagcccaagg ctgccccctc ggtcactctg 360
ttcccgcc 368
<210> 11
<211> 118
<212> PRT
<213> 1H10 heavy chain variable region amino acid sequence
<400> 11
Val His Ser Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln
1 5 10 15
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Val Glu Ala Phe
20 25 30
Ser Thr Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
35 40 45
Glu Trp Val Ala Asn Ile Asn Arg Asp Gly Ser Gln Lys Tyr Tyr Val
50 55 60
Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser
65 70 75 80
Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val
85 90 95
Tyr Tyr Cys Met Ser Gly Tyr Asp Ser Gly His Trp Gly Gln Gly Ser
100 105 110
Leu Val Thr Val Ser Ser
115
<210> 12
<211> 130
<212> PRT
<213> 3 lambda 5 light chain variable region amino acid sequence
<400> 12
Phe Asn Ser Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser
1 5 10 15
Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val
20 25 30
Thr Ser Gly Leu Tyr Ala Tyr Trp Phe Gln Gln Lys Pro Gly Gln Val
35 40 45
Pro Arg Thr Leu Ser Thr Gly Ala Val Ile Tyr Asn Ile Ser Asn Lys
50 55 60
Gln Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys
65 70 75 80
Ala Ala Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala Asp Tyr
85 90 95
Tyr Cys Leu Leu Ser Tyr Ser Arg Thr Arg Val Phe Gly Gly Gly Thr
100 105 110
Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu
115 120 125
Phe Pro
130
<210> 13
<211> 118
<212> PRT
<213> 1H16 heavy chain variable region amino acid sequence
<400> 13
Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
1 5 10 15
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
20 25 30
Ser Thr Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
35 40 45
Glu Trp Val Ala Asn Ile Asn Arg Asp Gly Ser Gln Lys Tyr Tyr Val
50 55 60
Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser
65 70 75 80
Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val
85 90 95
Tyr Tyr Cys Met Ser Gly Tyr Asp Ser Gly His Trp Gly Gln Gly Ser
100 105 110
Leu Val Thr Val Ser Ser
115
<210> 14
<211> 128
<212> PRT
<213> 3 lambda 7 light chain variable region amino acid sequence
<400> 14
Ser Asn Ser Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser
1 5 10 15
Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val
20 25 30
Thr Ser Gly Leu Tyr Ala Tyr Trp Thr Val Thr Phe Gln Gln Lys Pro
35 40 45
Gly Gln Val Pro Arg Thr Leu Ile Tyr Asn Ile Ser Asn Lys Gln Ser
50 55 60
Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala
65 70 75 80
Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys
85 90 95
Leu Leu Ser Tyr Ser Arg Thr Arg Val Phe Gly Gly Gly Thr Lys Leu
100 105 110
Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro
115 120 125
<210> 15
<211> 116
<212> PRT
<213> 1H17 heavy chain variable region amino acid sequence
<400> 15
Val His Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
1 5 10 15
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
20 25 30
Ser Thr Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
35 40 45
Glu Trp Val Ala Asn Arg Asp Gly Ser Gln Lys Tyr Tyr Val Asp Ser
50 55 60
Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Met Ser Gly Tyr Asp Ser Gly His Trp Gly Gln Gly Ser Thr Val
100 105 110
Thr Val Ser Ser
115
<210> 16
<211> 123
<212> PRT
<213> 3 lambda 8 light chain variable region amino acid sequence
<400> 16
Ser Trp Ala Asn Phe Met Leu Thr Gln Glu Pro Ser Leu Thr Val Ser
1 5 10 15
Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val
20 25 30
Thr Ser Gly Leu Tyr Ala Tyr Trp Phe Gln Gln Lys Pro Gly Gln Val
35 40 45
Pro Arg Thr Leu Ile Tyr Asn Ile Ser Asn Lys Gln Ser Trp Thr Pro
50 55 60
Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu
65 70 75 80
Ser Gly Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Leu Leu Ser Tyr Ser
85 90 95
Arg Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro
115 120
<210> 17
<211> 127
<212> PRT
<213> 1H3 heavy chain variable region amino acid sequence
<400> 17
Val His Ser Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
1 5 10 15
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
20 25 30
Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
35 40 45
Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Asn Lys Tyr Tyr Ala Asp
50 55 60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80
Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Ala Arg Ala Pro Asp Cys Ser Gly Gly Ser Cys Ser Thr Glu
100 105 110
Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125
<210> 18
<211> 123
<212> PRT
<213> 3 lambda 1 light chain variable region amino acid sequence
<400> 18
Ser Trp Ala Gln Ser Val Leu Thr Gln Glu Pro Ser Leu Thr Val Ser
1 5 10 15
Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val
20 25 30
Thr Ser Gly Leu Tyr Ala Tyr Trp Phe Gln Gln Lys Pro Gly Gln Val
35 40 45
Pro Arg Thr Leu Ile Tyr Asn Ile Ser Asn Lys Gln Ser Trp Thr Pro
50 55 60
Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu
65 70 75 80
Ser Gly Ala Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Leu Leu Ser
85 90 95
Tyr Ser Arg Thr Arg Val Phe Gly Thr Lys Leu Thr Val Leu Gly Gln
100 105 110
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro
115 120
<210> 19
<211> 122
<212> PRT
<213> 1H18 heavy chain variable region amino acid sequence
<400> 19
Val His Ser Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln
1 5 10 15
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
20 25 30
Ser Thr Tyr Trp Met Asn Trp Val Arg Leu Ser Gln Thr Pro Gly Lys
35 40 45
Gly Leu Glu Trp Val Ala Asn Ile Asn Arg Asp Gly Ser Gln Lys Tyr
50 55 60
Tyr Val Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Leu Ser Asp
65 70 75 80
Asn Ala Lys Ser Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp
85 90 95
Asp Thr Ala Val Tyr Tyr Cys Met Ser Gly Tyr Asp Ser Gly His Trp
100 105 110
Gly Gln Gly Ser Thr Val Thr Val Ser Ser
115 120
<210> 20
<211> 122
<212> PRT
<213> 3 lambda 10 light chain variable region amino acid sequence
<400> 20
Ser Asn Ser Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser
1 5 10 15
Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val
20 25 30
Thr Ser Gly Leu Tyr Ala Gln Gln Lys Pro Gly Gln Val Pro Arg Thr
35 40 45
Leu Ile Tyr Asn Ile Ser Asn Lys Gln Ser Trp Thr Pro Ala Arg Phe
50 55 60
Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala
65 70 75 80
Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Leu Leu Ser Tyr Ser Arg
85 90 95
Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro
100 105 110
Lys Ala Ala Pro Ser Val Thr Leu Phe Pro
115 120

Claims (10)

1. A high affinity fully human monoclonal antibody to rabies virus having a heavy chain variable region and a light chain variable region:
(I) the amino acid sequence of the heavy chain variable region has the nucleotide sequence of the heavy chain variable region shown in any one of SEQ ID NOs 11, 13, 15, 17 and 19; or has an amino acid sequence which is formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in any one of SEQ ID NO. 11, 13, 15, 17 and 19 and has the same function;
(II) the amino acid sequence of the light chain variable region has the nucleotide sequence of the light chain variable region as shown in any one of SEQ ID NOs 12, 14, 16, 18 and 20; or an amino acid sequence which is formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in any one of SEQ ID NO 12, 14, 16, 18 and 20 and has the same function.
2. The monoclonal antibody of claim 1, which has any one of the following groups of heavy chain variable regions and light chain variable regions:
(i) the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 11; the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 12;
(ii) the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 13; the amino acid sequence of the light chain variable region is shown as SEQ ID NO: 14;
(iii) the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 15; the amino acid sequence of the light chain variable region is shown as SEQ ID NO: 16;
(iv) the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO: 17; the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 18;
(v) the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 19; the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 20.
3. The monoclonal antibody of claim 1, wherein the antibody specifically binds to rabies virus G protein.
4. A nucleic acid molecule encoding the monoclonal antibody of any one of claims 1-3, having the nucleotide sequence of the heavy chain variable region as set forth in any one of SEQ ID NOs 1, 3, 5, 7 and 9; and the variable region of the light chain as set forth in any one of SEQ ID NOs 2, 4, 6, 8 and 10.
5. The nucleic acid molecule of claim 4, having any one of the following groups of heavy chain variable regions and light chain variable regions:
(i) the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO: 1; the nucleotide sequence of the light chain variable region is shown as SEQ ID NO. 2;
(ii) the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO. 3; the nucleotide sequence of the light chain variable region is shown as SEQ ID NO. 4;
(iii) the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO. 5; the nucleotide sequence of the light chain variable region is shown as SEQ ID NO. 6;
(iv) the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO. 7; the nucleotide sequence of the light chain variable region is shown as SEQ ID NO. 8;
(v) the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO. 9; the variable region in the light chain has the nucleotide sequence shown in SEQ ID NO 10.
6. An expression vector comprising the nucleic acid molecule of claim 4 or 5.
7. A host cell comprising the expression vector of claim 6.
8. The method for producing the monoclonal antibody of claim 1, comprising the steps of:
(1) memory B cell sorting: separating peripheral blood mononuclear cells from blood samples of volunteers infected with rabies viruses, and sorting the peripheral blood mononuclear cells to obtain memory B cells;
(2) in-vitro activation culture and positive hole screening of memory B cells: activating the memory B cells into plasma cells, detecting secretory IgG antibodies of the memory B cells after the memory B cells are activated into the plasma cells in vitro by ELISA, and screening to obtain positive holes;
(3) constructing and screening an antibody variable region gene library: carrying out reverse transcription on the positive hole cells to obtain cDNA, and amplifying genes of heavy chain variable regions and light chain variable regions of the antibodies;
(4) constructing a library of antibody gene heavy chain variable regions and light chain variable regions: respectively connecting the amplified genes of the heavy chain variable region and the light chain variable region of the antibody to an expression vector;
(5) screening of antibody heavy chain variable region and light chain variable region genes: the recombinant plasmid was co-transfected into HEK293T cells for expression.
9. Use of the monoclonal antibody or binding fragment thereof of any one of claims 1-3 in the manufacture of a medicament for detecting, treating or preventing rabies virus infection.
10. A composition comprising an antibody mixture of one or more of the monoclonal antibodies of any one of claims 1-3 in a therapeutically effective amount, and a pharmaceutically acceptable carrier.
CN202110498615.1A 2021-05-08 2021-05-08 High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof Active CN113185608B (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202110498615.1A CN113185608B (en) 2021-05-08 2021-05-08 High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof
CN202210649220.1A CN115260307B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210649233.9A CN115260308B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210655968.2A CN114957458B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210655944.7A CN114920835B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110498615.1A CN113185608B (en) 2021-05-08 2021-05-08 High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN202210649220.1A Division CN115260307B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210655968.2A Division CN114957458B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210649233.9A Division CN115260308B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210655944.7A Division CN114920835B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof

Publications (2)

Publication Number Publication Date
CN113185608A true CN113185608A (en) 2021-07-30
CN113185608B CN113185608B (en) 2022-08-09

Family

ID=76984259

Family Applications (5)

Application Number Title Priority Date Filing Date
CN202210655968.2A Active CN114957458B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210649233.9A Active CN115260308B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210655944.7A Active CN114920835B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210649220.1A Active CN115260307B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202110498615.1A Active CN113185608B (en) 2021-05-08 2021-05-08 High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN202210655968.2A Active CN114957458B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210649233.9A Active CN115260308B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210655944.7A Active CN114920835B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof
CN202210649220.1A Active CN115260307B (en) 2021-05-08 2021-05-08 High-affinity anti-rabies virus fully human monoclonal antibody and application thereof

Country Status (1)

Country Link
CN (5) CN114957458B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114231502A (en) * 2021-10-29 2022-03-25 吉林大学 Recombinant rabies virus for expressing novel coronavirus RBD protein and application thereof
CN114853886A (en) * 2022-05-23 2022-08-05 南昌大学 Fully human monoclonal antibody with high affinity for human cytomegalovirus and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958774B (en) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 Anti-rabies virus monoclonal antibody, hybridoma cell strain secreting antibody and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103910796A (en) * 2013-01-08 2014-07-09 广州泰诺迪生物科技有限公司 Completely humanized neutralizing antibody for anti-rabies viruses
WO2017027805A1 (en) * 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof
CN106432486A (en) * 2016-11-29 2017-02-22 广州泰诺迪生物科技有限公司 Fully human anti-rabies virus neutralizing antibody and application thereof
CN111333723A (en) * 2018-08-09 2020-06-26 北京智仁美博生物科技有限公司 Monoclonal antibody aiming at rabies virus G protein and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645173B1 (en) * 1989-03-29 1994-06-17 Pasteur Institut CLONING AND EXPRESSION OF GENES ENCODING PEPTIDES AND / OR FRAGMENTS OF MOKOLA VIRUS PEPTIDES, APPLICATION TO THE PREPARATION OF A V
SI1749029T1 (en) * 2004-05-27 2011-06-30 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
CN101696242B (en) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 Human anti rabies virus neutralizing antibody Fab as well as preparation method and application thereof
CN101812132B (en) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing antibody (RVFab3) against rabies virus glycoprotein
CN101812131B (en) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein
CN101812130B (en) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing antibody (RVFab5) against rabies virus glycoprotein
CN103087155B (en) * 2013-01-20 2014-10-29 复旦大学 Rabies virus vaccine enhancin, gene for coding enhancin and application of enhancin
CN112430264A (en) * 2020-11-18 2021-03-02 南京医科大学 Anti-rabies virus G protein scFv20 antibody and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103910796A (en) * 2013-01-08 2014-07-09 广州泰诺迪生物科技有限公司 Completely humanized neutralizing antibody for anti-rabies viruses
WO2017027805A1 (en) * 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof
CN106432486A (en) * 2016-11-29 2017-02-22 广州泰诺迪生物科技有限公司 Fully human anti-rabies virus neutralizing antibody and application thereof
CN111333723A (en) * 2018-08-09 2020-06-26 北京智仁美博生物科技有限公司 Monoclonal antibody aiming at rabies virus G protein and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHABAUD-RIOU, M; MORENO, N; RIOU, P: "G-protein based ELISA as a potency test for rabies vaccines", 《BIOLOGICALS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114231502A (en) * 2021-10-29 2022-03-25 吉林大学 Recombinant rabies virus for expressing novel coronavirus RBD protein and application thereof
CN114853886A (en) * 2022-05-23 2022-08-05 南昌大学 Fully human monoclonal antibody with high affinity for human cytomegalovirus and application thereof
CN114853886B (en) * 2022-05-23 2023-11-28 南昌大学 Fully human monoclonal antibody with high affinity against human cytomegalovirus and application thereof

Also Published As

Publication number Publication date
CN114957458B (en) 2023-10-31
CN115260307A (en) 2022-11-01
CN115260307B (en) 2024-02-09
CN114920835B (en) 2024-01-02
CN115260308A (en) 2022-11-01
CN115260308B (en) 2024-02-09
CN113185608B (en) 2022-08-09
CN114920835A (en) 2022-08-19
CN114957458A (en) 2022-08-30

Similar Documents

Publication Publication Date Title
CN113185608B (en) High-affinity rabies virus-resistant fully-humanized monoclonal antibody and application thereof
CN105669838B (en) Neutralizing epitopes from varicella-zoster virus gE protein and antibodies thereto
CN114920833B (en) New coronavirus RBD specific monoclonal antibody and application
RU2613421C2 (en) HIGH-AFFINITY HUMAN ANTIBODIES TO CYTOMEGALOVIRUS (CMV) gB PROTEIN
CN110551213B (en) Anti-filovirus monoclonal neutralizing antibody and preparation method and application thereof
TW202208424A (en) Anti-novel coronavirus bispecific antibody and use thereof
CN113234147B (en) Fully human monoclonal antibody with high affinity for resisting hepatitis C virus and application thereof
CN111620944B (en) Fully humanized anti-hepatitis B virus monoclonal antibody, preparation method and application thereof
CN110590942B (en) Fully human monoclonal antibody for neutralizing enterovirus 71 and application thereof
CN105061590B (en) For the bispecific antibody and application thereof of hepatitis B surface albumen
CN112661841B (en) Fully human monoclonal antibody 17-2 for neutralizing neoepitope of new coronavirus and application thereof
CN114316040B (en) Fully human monoclonal antibody for resisting novel coronavirus and application thereof
CN109553680B (en) Monoclonal antibody ZKns4B8 and application thereof
CN109535249B (en) Monoclonal antibody ZKns3G2 and application thereof
CN110655572B (en) Monoclonal antibody for resisting filovirus GP protein and application thereof
CN109503712B (en) Monoclonal antibody ZKns2E11 and application thereof
CN114853886B (en) Fully human monoclonal antibody with high affinity against human cytomegalovirus and application thereof
WO2017206621A1 (en) Neutralizing human monoclonal antibody 8d6 against hcv infection
CN114591427B (en) Mouse anti-MPT 32 protein hybridoma cell line 13B12, monoclonal antibody based on same and application thereof
CN109897106A (en) Nano antibody and its preparation method and application
CN116444663A (en) Encephalitis B virus antibody and application thereof
CN114480308A (en) Recombinant baculovirus and preparation method and application thereof
CN116589571A (en) Encephalitis B virus antibody and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant